Precigen (PGEN) Preferred Stock Liabilities (2012 - 2013)
Precigen (PGEN) posted quarterly Preferred Stock Liabilities of $35.2 million for Q2 2013, up 2490.15% quarter-over-quarter from $1.4 million in Q4 2012.
Powered by 
Analysis
Precigen (PGEN) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Precigen (PGEN) has reported Preferred Stock Liabilities for 2 consecutive years, with $35.2 million the latest figure, recorded in Q2 2013.
- In Q2 2013, Preferred Stock Liabilities changed N/A year-over-year to $35.2 million; the TTM figure through Jun 2013 stood at $35.2 million (changed N/A YoY), while the FY2012 annual figure was $1.4 million, down 95.16% from the prior year.
- Preferred Stock Liabilities rose to $35.2 million in Q2 2013 per PGEN's latest filing, from $1.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $35.2 million in Q2 2013 and bottomed at $1.4 million in Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | - |